P
Patrick M. Forde
Researcher at Johns Hopkins University
Publications - 204
Citations - 9190
Patrick M. Forde is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 37, co-authored 129 publications receiving 5059 citations. Previous affiliations of Patrick M. Forde include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde,Jamie E. Chaft,Kellie N. Smith,Valsamo Anagnostou,Tricia R. Cottrell,Matthew D. Hellmann,Marianna Zahurak,Stephen C. Yang,David R. Jones,Stephen R. Broderick,Richard J. Battafarano,Moises J. Velez,Natasha Rekhtman,Zachary T. Olah,Jarushka Naidoo,Kristen A. Marrone,Franco Verde,Haidan Guo,Jiajia Zhang,Justina X. Caushi,Hok Yee Chan,John-William Sidhom,Robert B. Scharpf,James R. White,Edward Gabrielson,Hao Wang,Gary L. Rosner,Valerie W. Rusch,Jedd D. Wolchok,Taha Merghoub,Janis M. Taube,Victor E. Velculescu,Suzanne L. Topalian,Julie R. Brahmer,Drew M. Pardoll +34 more
TL;DR: Nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors, and the tumor mutational burden was predictive of the pathological response to PD‐1 blockade.
Journal ArticleDOI
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou,Kellie N. Smith,Patrick M. Forde,Noushin Niknafs,Rohit Bhattacharya,James R. White,Theresa Zhang,Vilmos Adleff,Jillian Phallen,Neha Wali,Carolyn Hruban,Violeta Beleva Guthrie,Kristen Rodgers,Jarushka Naidoo,Hyunseok Kang,William H. Sharfman,Christos S. Georgiades,Franco Verde,Peter B. Illei,Qing Kay Li,Edward Gabrielson,Malcolm V. Brock,Cynthia A. Zahnow,Stephen B. Baylin,Robert B. Scharpf,Julie R. Brahmer,Rachel Karchin,Drew M. Pardoll,Victor E. Velculescu +28 more
TL;DR: This work demonstrates for the first time that acquired resistance to immune checkpoint blockade can arise in association with the evolving landscape of mutations, some of which encode tumor neoantigens recognizable by T cells.
Journal ArticleDOI
Genome-wide cell-free DNA fragmentation in patients with cancer
Stephen Cristiano,Alessandro Leal,Jillian Phallen,Jacob Fiksel,Vilmos Adleff,Daniel C. Bruhm,Sarah Østrup Jensen,Jamie E. Medina,Carolyn Hruban,James R. White,Doreen N. Palsgrove,Noushin Niknafs,Valsamo Anagnostou,Patrick M. Forde,Jarushka Naidoo,Kristen A. Marrone,Julie R. Brahmer,Brian Woodward,Hatim Husain,Karlijn L. van Rooijen,Mai Britt Worm Ørntoft,Anders Husted Madsen,Cornelis J.H. van de Velde,Marcel Verheij,Annemieke Cats,Cornelis J. A. Punt,Geraldine R. Vink,Nicole C.T. van Grieken,Miriam Koopman,Remond J.A. Fijneman,Julia S. Johansen,Hans Jørgen Nielsen,Gerrit A. Meijer,Claus L. Andersen,Robert B. Scharpf,Victor E. Velculescu +35 more
TL;DR: An approach to evaluate fragmentation patterns of cell-free DNA across the genome was developed, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles.
Journal ArticleDOI
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Patrick M. Forde,Jonathan Spicer,Shun Lu,Mariano Provencio,Tetsuya Mitsudomi,Mark M. Awad,Enriqueta Felip,Stephen R. Broderick,Julie R. Brahmer,J. Swanson,Keith M. Kerr,Changli Wang,Tudor Ciuleanu,Gene Brian Saylors,Fumihiro Tanaka,Hiroyuki Ito,Keke Chen,Moishe Liberman,Everett E. Vokes,Janis M. Taube,C. Dorange,Jun Bo Cai,Joseph Fiore,Anthony Jarkowski,David Balli,Mark Sausen,Dimple Pandya,Christophe Y Calvet,Nicolas Girard +28 more
TL;DR: In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone.
Journal ArticleDOI
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Alexa B. Schrock,Garrett M. Frampton,James Suh,Zachary R. Chalmers,Margaret Rosenzweig,Rachel L. Erlich,Balazs Halmos,Jonathan H. Goldman,Patrick M. Forde,Kurt Leuenberger,Nir Peled,Gregory P. Kalemkerian,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Siraj M. Ali,Sai-Hong Ignatius Ou +16 more
TL;DR: Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all majorNSCLC histologic subtypes with an overall frequency of 2.7%.